Crystalline Phenyltriazolyl Acrylamides Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for robust, high-yield synthetic methods to produce phenyltriazolyl acrylamides, which are selective inhibitors of nuclear export (SINEs) used as anti-cancer medications, and also for crystalline forms of these compounds for pharmaceutical compositions.
Innovation Solution
The method involves reacting a compound with a Pd catalyst and inorganic bases in specific solvents and conditions to obtain crystalline Forms I and II of the phenyltriazolyl acrylamides, characterized by distinct X-ray powder diffraction peaks, suitable for treatment of CRM-1 associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If multistep synthetic schemes are employed to produce phenyltriazolyl acrylamides, then stereoselectivity can be controlled, but yield and process robustness deteriorate
Solution Approach 1:
The patent divides the synthetic method into two distinct parts: a stereoselective step (Suzuki coupling reaction) that establishes the chiral center, and a separate cyclization step that forms the triazolyl acrylamide core. This segmentation allows each step to be optimized independently, achieving both high stereoselectivity and improved yield by avoiding the need for tight control of multiple conditions simultaneously.
Solution Approach 2:
The patent employs a chiral auxiliary group (such as a chiral amine or carbamate) that is introduced beforehand to control stereochemistry during the Suzuki coupling step. This preliminary chiral induction allows the stereoselective step to proceed with high enantioselectivity, and the chiral auxiliary is subsequently removed in a final step, delivering the desired stereoisomer in high yield.
2Manufacturing precision
If tight control of conditions is applied in multistep schemes, then stereoselectivity is ensured, but process robustness and scalability deteriorate
Solution Approach 1:
By separating the synthesis into a Suzuki coupling step (with chiral control via auxiliary groups) and a cyclization step, the patent reduces the complexity of condition control. Each step has more relaxed conditions, making the overall process more robust and scalable while maintaining stereoselectivity through the chiral auxiliary mechanism.
Solution Approach 2:
The patent utilizes chiral auxiliary groups that can be introduced under standard conditions and removed under different conditions, allowing the stereoselective step to proceed with conventional reagents and conditions. This parameter change approach (using temporary chiral groups that can be easily installed and removed) makes the process more robust compared to requiring tight control of chiral catalysts or reagents throughout the entire synthesis.
3Ease of manufacture
If conventional synthetic methods are used, then existing knowledge can be applied, but production yield and crystalline form availability deteriorate
Solution Approach 1:
The patent modifies conventional Suzuki coupling conditions by introducing chiral auxiliary groups and specific base conditions (such as carbonates or hydroxides) to achieve both high yield and stereoselectivity in a single step. This parameter change approach maintains ease of manufacture while dramatically improving yield compared to conventional multistep methods.
Solution Approach 2:
The patent employs a universal chiral auxiliary group strategy that can be applied across different substrates and conditions. The same type of chiral auxiliary (e.g., chiral amine or carbamate) can control stereochemistry in various Suzuki coupling reactions, making the method broadly applicable while maintaining high yield and stereoselectivity throughout the synthesis sequence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of crystalline forms of phenyltriazolyl acrylamides with improved yield and stability, facilitating their use in pharmaceutical compositions for treating CRM-1 associated diseases.
Implementation Method 1
reacting a compound with a Pd catalyst and inorganic bases in specific solvents and conditions to obtain crystalline Forms I and II of the phenyltriazolyl acrylamides
Implementation Method 2
reacting a compound with a Pd catalyst and inorganic bases in specific solvents and conditions to obtain crystalline Forms I and II of the phenyltriazolyl acrylamides
Implementation Method 3
crystalline Forms I and II of the compound represented by Structural Formula (VII), compositions comprising crystalline Forms I and II
Implementation Method 4
characterized by distinct X-ray powder diffraction peaks
Data Source
AI summary
The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.